Cargando…
Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer
BACKGROUND: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer. ME...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619565/ https://www.ncbi.nlm.nih.gov/pubmed/26497569 http://dx.doi.org/10.1186/s12943-015-0456-4 |
_version_ | 1782397132128387072 |
---|---|
author | Bauer, Jessica Ozden, Ozkan Akagi, Naomi Carroll, Timothy Principe, Daniel R. Staudacher, Jonas J. Spehlmann, Martina E. Eckmann, Lars Grippo, Paul J. Jung, Barbara |
author_facet | Bauer, Jessica Ozden, Ozkan Akagi, Naomi Carroll, Timothy Principe, Daniel R. Staudacher, Jonas J. Spehlmann, Martina E. Eckmann, Lars Grippo, Paul J. Jung, Barbara |
author_sort | Bauer, Jessica |
collection | PubMed |
description | BACKGROUND: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer. METHOD: Mitogenic signaling/growth factor receptor status and p21 localization were correlated in primary colon cancers and intestinal tumors from either AOM/DSS treated ACVR2A (activin receptor 2) −/− or wild type mice. Colon cancer cell lines (+/− SMAD4) were interrogated for ligand-induced PI3K and MEK/ERK pathway activation and downstream protein/phospho-isoform expression/association after knockdown and pharmacologic inhibition of pathway members. EMT was assessed using epithelial/mesenchymal markers and migration assays. RESULTS: In primary colon cancers, loss of nuclear p21 correlated with upstream activation of activin/PI3K while nuclear p21 expression was associated with TGFβ/MEK/ERK pathway activation. Activin, but not TGFβ, led to PI3K activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation. In contrast, TGFβ increased p21 via MEK/ERK pathway through a SMAD4-dependent mechanism. While activin induced EMT via PI3K, TGFβ induced EMT via MEK/ERK activation. In vivo, loss of ACVR2A resulted in loss of pAkt, consistent with activin-dependent PI3K signaling. CONCLUSION: Although activin and TGFβ share growth suppressive SMAD signaling in colon cancer, they diverge in their SMAD4-independent pro-migratory signaling utilizing distinct mitogenic signaling pathways that affect EMT. p21 localization in colon cancer may determine a dominant activin versus TGFβ ligand signaling phenotype warranting further validation as a therapeutic biomarker prior to targeting TGFβ family receptors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0456-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4619565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46195652015-10-26 Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer Bauer, Jessica Ozden, Ozkan Akagi, Naomi Carroll, Timothy Principe, Daniel R. Staudacher, Jonas J. Spehlmann, Martina E. Eckmann, Lars Grippo, Paul J. Jung, Barbara Mol Cancer Research BACKGROUND: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer. METHOD: Mitogenic signaling/growth factor receptor status and p21 localization were correlated in primary colon cancers and intestinal tumors from either AOM/DSS treated ACVR2A (activin receptor 2) −/− or wild type mice. Colon cancer cell lines (+/− SMAD4) were interrogated for ligand-induced PI3K and MEK/ERK pathway activation and downstream protein/phospho-isoform expression/association after knockdown and pharmacologic inhibition of pathway members. EMT was assessed using epithelial/mesenchymal markers and migration assays. RESULTS: In primary colon cancers, loss of nuclear p21 correlated with upstream activation of activin/PI3K while nuclear p21 expression was associated with TGFβ/MEK/ERK pathway activation. Activin, but not TGFβ, led to PI3K activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation. In contrast, TGFβ increased p21 via MEK/ERK pathway through a SMAD4-dependent mechanism. While activin induced EMT via PI3K, TGFβ induced EMT via MEK/ERK activation. In vivo, loss of ACVR2A resulted in loss of pAkt, consistent with activin-dependent PI3K signaling. CONCLUSION: Although activin and TGFβ share growth suppressive SMAD signaling in colon cancer, they diverge in their SMAD4-independent pro-migratory signaling utilizing distinct mitogenic signaling pathways that affect EMT. p21 localization in colon cancer may determine a dominant activin versus TGFβ ligand signaling phenotype warranting further validation as a therapeutic biomarker prior to targeting TGFβ family receptors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0456-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-24 /pmc/articles/PMC4619565/ /pubmed/26497569 http://dx.doi.org/10.1186/s12943-015-0456-4 Text en © Bauer et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Bauer, Jessica Ozden, Ozkan Akagi, Naomi Carroll, Timothy Principe, Daniel R. Staudacher, Jonas J. Spehlmann, Martina E. Eckmann, Lars Grippo, Paul J. Jung, Barbara Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer |
title | Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer |
title_full | Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer |
title_fullStr | Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer |
title_full_unstemmed | Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer |
title_short | Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer |
title_sort | activin and tgfβ use diverging mitogenic signaling in advanced colon cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619565/ https://www.ncbi.nlm.nih.gov/pubmed/26497569 http://dx.doi.org/10.1186/s12943-015-0456-4 |
work_keys_str_mv | AT bauerjessica activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT ozdenozkan activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT akaginaomi activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT carrolltimothy activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT principedanielr activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT staudacherjonasj activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT spehlmannmartinae activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT eckmannlars activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT grippopaulj activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer AT jungbarbara activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer |